Baxalta, recently spun out from Baxter, is charging toward its first drug approvals under a new identity, publishing positive results for a bleeding treatment awaiting word from the FDA.
AstraZeneca is widening its long-standing relationship with Isis Pharmaceuticals, betting on the company's proprietary approach to RNA-targeted therapies in hopes of expanding its early-stage pipeline.
Global Blood Therapeutics, a graduate of Third Rock Ventures' startup academy, set terms for an IPO worth as much as $124 million, looking to raise money for its oral sickle cell disease program.
Merck's Ebola vaccine, in development alongside NewLink Genetics, protected 100% of patients from contracting the virus in interim results from an ongoing study, giving rise to hopes it can help prevent future outbreaks.
Amgen, long criticized over its appetite for moonshot R&D projects, scaled back its research budget by more than 10% in the second quarter, part of a companywide effort to cut costs while advancing a make-or-break pipeline.
Amgen shocked the industry in May when it cut ties with an AstraZeneca-partnered psoriasis treatment after spotting alarming rates of suicidal thoughts among patients taking the antibody. But its former collaborator is remaining optimistic about the once-promising treatment, tentatively moving toward an FDA filing.
Boehringer Ingelheim has agreed to hand over as much as $730 million to South Korean drugmaker Hanmi Pharmaceutical in exchange for the rights to a midstage treatment for lung cancer, betting the drug can stand out in a crowded field.
Sprint Bioscience (STO:SPRINT) has entered into a cancer research collaboration with Bayer, handing over the rights to an early-stage tumor metabolism program in return for €190 million ($210 million) in upfront and milestone payments.
Esperion, developing a pill it hopes can eventually cut in on some would-be blockbusters, posted new study results showing that its drug both reduced bad cholesterol and improved inflammation.
Merck, maker of the pioneering immuno-oncology treatment Keytruda, is investing in the next generation of cancer therapies that harness the body's natural defenses, agreeing to pay as much as $605 million for an Israeli biotech at work in the field.